AR
Design armored CAR-T cells with cytokine payloads and resistance mechanisms.
FreedomIntelligence/OpenClaw-Medical-Skills查看
数据与复现
TO
tooluniverse-gwas-drug-discovery
维护者 FreedomIntelligence · 最近更新 2026年4月1日
This skill bridges genetic discoveries from GWAS with drug development by: 1. **Identifying genetic risk factors** - Finding genes associated with diseases 2. **Assessing druggability** - Evaluating which genes can be targeted by drugs 3. **Prioriti.
原始来源
FreedomIntelligence/OpenClaw-Medical-Skills
https://github.com/FreedomIntelligence/OpenClaw-Medical-Skills/tree/main/skills/tooluniverse-gwas-drug-discovery
- 维护者
- FreedomIntelligence
- 许可
- MIT
- 最近更新
- 2026年4月1日
技能摘要
来自 SKILL.md 的关键信息
核心说明
- 转换 genome-wide association studies (GWAS) into actionable drug targets 、 repurposing opportunities。
- This skill bridges genetic discoveries ，面向 GWAS ，支持 drug development by：。
- 1. Identifying genetic risk factors - Finding genes associated ，支持 diseases 2. Assessing druggability - Evaluating which genes can be targeted by drugs 3. Prioritizing targets - Ranking candidates by genetic evidence strength 4. Finding existing drugs - Discovering approved/investigational compounds 5. Identifying repurposing opportunities - Matching drugs to new indications。
原始文档
SKILL.md 摘录
Why This Matters
From Genetics to Therapeutics: GWAS has identified thousands of disease-associated variants, but most haven't been translated into therapies. This skill accelerates that translation.
Success Stories:
- PCSK9 (cholesterol) → Alirocumab, Evolocumab (approved 2015)
- IL-6R (rheumatoid arthritis) → Tocilizumab (approved 2010)
- CTLA4 (autoimmunity) → Abatacept (approved 2005)
- CFTR (cystic fibrosis) → Ivacaftor (approved 2012)
Genetic Evidence Doubles Success Rate: Targets with genetic support have 2x higher probability of clinical approval (Nelson et al., Nature Genetics 2015).
1. GWAS Evidence Strength
Not all genetic associations are equal. Consider:
- P-value - Statistical significance (genome-wide: p < 5×10⁻⁸)
- Effect size (beta/OR) - Magnitude of genetic effect
- Replication - Confirmed in multiple studies
- Sample size - Larger studies = more reliable
- Population diversity - Validated across ancestries
2. Druggability Criteria
A good drug target must be:
- Accessible - Protein location allows drug binding (extracellular > intracellular)
- Modality match - Target class fits drug type (GPCR → small molecule, receptor → antibody)
- Tractable - Binding pocket suitable for drug design
- Safe - Minimal off-target effects, not essential in all tissues
适用场景
- 适合在discovering drug targets ，面向 GWAS data，finding drug repurposing opportunities ，面向 genetic associations，或 translating GWAS findings into therapeutic leads时使用。
不适用场景
- Do not rely on this catalog entry alone ，用于 installation 或 maintenance details。
相关技能
相关技能
AR
数据与复现
arxiv-search
Search arXiv physics, math, and computer science preprints using natural language queries. Powered by Valyu semantic sea…
FreedomIntelligence/OpenClaw-Medical-Skills查看
AU
Autonomous oncology research agent: literature mining, trial matching, biomarker analysis, and treatment hypothesis gene…
FreedomIntelligence/OpenClaw-Medical-Skills查看
BI
Preprocesses cell-free DNA sequencing data including adapter trimming, alignment optimized for short fragments, and UMI-…
FreedomIntelligence/OpenClaw-Medical-Skills查看